Registration of Kazakh Cancer Drug Delayed, Says Science Minister

Testing of the cancer drug continues in Kazakhstan. Registration is planned for this year, Orda.kz reports.

This was announced by Minister of Science and Higher Education Sayasat Nurbek. According to him, the drug DVC is being developed by the National Laboratory of Astana on the basis of Nazarbayev University. Last year, it had already passed the stage of clinical trials on humans.

"I think we will submit this medicine for registration by the end of this year. The delay is caused by the fact that we are complying with the requirements of national legislation, but now we also need to comply with international regulations for registration. Everything is very strict there. Additional clinical trials on living people were required," he said at a government briefing. 

Research is now continuing at a new clinical base — the Astana Oncology Center. Regional cancer centers, including in Karaganda, have also joined the work. Previously, tests were also carried out in Almaty.

The delay in the drug's release, according to him, is due to the need to comply not only with national requirements but also with international standards, including EAEU regulations. This required additional clinical trials.

The authorities expect to complete all the necessary procedures by the end of the year and submit the drug for registration in Kazakhstan. After obtaining permission from the Ministry of Health and the National Center for Drug Examination, it will be able to be used in the country's clinics.

Original author: Ilya Astakhov

Read also:

• Kazakhstani Scientists Are Preparing a Cancer-Prevention Supplement From Tomatoes and Watermelons
• Domestic Cancer Drug in Development: Clinical Trials Underway in Kazakhstan
• Ministry of Health Reveals Leading Causes of Death Among Kazakhstanis